Corifollitropin-α is useful for low and normal responders, but what about hyperresponders?

Blumenfeld, Zeev

doi:10.1016/j.fertnstert.2018.12.013

Cited by 2 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At this point, it is of interest to note that corifollitropin alfa has been proposed as an alternative option for daily recombinant FSH injections in POR patients undergoing ovarian stimulation in IVF treatment [ 54 , 55 , 56 ]. Corifollitropin alpha constitutes a hybrid molecule generated by the fusion of human Chorionic Gonadotropin β subunit carboxyl-terminal peptide with human FSH beta chain [ 57 , 58 ].…”

Section: Managing Poor Ovarian Responsementioning

confidence: 99%

“…Considering corifollitropin alfa’s pharmacodynamic, it has been voiced that a single injection of corifollitropin alfa could provide the same stimulation outcome as daily recombinant FSH administration, leading to a more patient-friendly stimulation protocol. This approach may alleviate patients’ anxiety levels related to the multiple injections that are typically required when employing recombinant FSH [ 55 ]. Data indicate that corifollitropin alfa administration is associated with a higher oocyte yield in women presenting with POR, while some of these studies suggest that corifollitropin alfa may better suit POR patients in comparison to daily FSH administration [ 54 , 56 , 60 ].…”

Section: Managing Poor Ovarian Responsementioning

confidence: 99%

“…In a recently published systematic review and meta-analysis, the authors provide evidence that corifollitropin alfa administration could be as effective as recombinant FSH for ovarian stimulation in POR patients [ 56 ]. However, there is a limited number of well-designed RCTs investigating the efficiency as well as the safety of corifollitropin alfa and for that reason several concerns have been raised by experts in the field [ 55 , 56 ]. Considering the aforementioned, no safe conclusions can be drawn with regard to the use of corifollitropin alfa in clinical practice.…”

Section: Managing Poor Ovarian Responsementioning

confidence: 99%

See 2 more Smart Citations

The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment

et al. 2020

View full text Add to dashboard Cite

Despite recent striking advances in assisted reproductive technology (ART), poor ovarian response (POR) diagnosis and treatment is still considered challenging. Poor responders constitute a heterogeneous cohort with the common denominator of under-responding to controlled ovarian stimulation. Inevitably, respective success rates are significantly compromised. As POR pathophysiology entails the elusive factor of compromised ovarian function, both diagnosis and management fuel an ongoing heated debate depicted in the literature. From the criteria employed for diagnosis to the plethora of strategies and adjuvant therapies proposed, the conundrum of POR still puzzles the practitioner. What is more, novel treatment approaches from stem cell therapy and platelet-rich plasma intra-ovarian infusion to mitochondrial replacement therapy have emerged, albeit not claiming clinical routine status yet. The complex and time sensitive nature of this subgroup of infertile patients indicates the demand for a consensus on a horizontally accepted definition, diagnosis and subsequent effective treating strategy. This critical review analyzes the standing criteria employed in order to diagnose and aptly categorize POR patients, while it proceeds to critically evaluate current and novel strategies regarding their management. Discrepancies in diagnosis and respective implications are discussed, while the existing diversity in management options highlights the need for individualized management.

show abstract